Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics

Teva Announces European Medicines Agency (EMA) Confirms Successful Validation of Reslizumab Marketing Authorization Application

July 28, 2015 8:00 AM EDT

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that it has successfully filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for reslizumab. Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.

Uncontrolled asthma remains a serious challenge for patients and healthcare professionals despite the availability of standard of care treatment, said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva... More

Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit

July 27, 2015 6:42 AM EDT

HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Teva's (NYSE and TASE: TEVA) announcement of its entry into an agreement to acquire Allergan's Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan.

Mylan Executive Chairman Robert J. Coury stated: "We congratulate Teva on their agreement to acquire Allergan's generics business and welcome their continued, and potentially enhanced, commitment to the generics industry. As Teva continues to move forward with their... More

Teva Reports Preliminary Second Quarter 2015 Results

July 27, 2015 4:47 AM EDT

$4.97 Billion in Revenue and $1.43 in Non-GAAP EPS

Raises 2015 EPS Guidance

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced preliminary financial results for the second quarter of 2015:

Revenues of approximately $4.97 billion, down 2% compared to the second quarter of 2014. Excluding the impact of foreign exchange fluctuations and the sale of U.S. OTC plants in July 2014, revenues increased 6% compared to the second quarter of 2014. Non-GAAP diluted earnings per share (EPS) of $1.43 in the... More

Teva Withdraws Proposal to Acquire Mylan

July 27, 2015 4:31 AM EDT

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (NASDAQ: MYL) and Teva does not intend to continue to pursue a transaction with Mylan at this time. Tevas decision to terminate the proposal to acquire Mylan follows todays announcement that Teva has entered into a definitive agreement with Allergan to acquire Allergan Generics.

In light of our strategic acquisition of Allergan... More

Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global Healthcare

July 27, 2015 4:30 AM EDT

Acquisition Strongly Reinforces Teva's Strategy, Accelerates the Creation of Its New Business Model and Opens a New Set of Possibilities for the Company In Generics and Specialty

Opportunity to Further Transform the Global Generics Space through Best-In-Class Generics Pipeline, R&D Capabilities, Operational Network, Supply Chain, Global Commercial Deployment and Infrastructure

Robust Generics Platform to Support Future Strategic Investment in Specialty

Teva Will Be a Top 10 Global Pharmaceutical Company

Enhanced Financial Profile with Strong, Diversified Revenues

... More